Eli Lilly has entered into a global partnership with AI-focused biotechnology firm Insilico Medicine to develop and commercialise medicines designed entirely using artificial intelligence, the companies announced Sunday. The agreement, valued at up to $2.75 billion (€2.39 billion), will allow Eli Lilly to leverage Insilico’s AI platform to accelerate drug discovery across multiple therapeutic areas.
Under the deal, Eli Lilly will hold exclusive worldwide rights to develop, manufacture, and commercialise novel oral therapeutics currently in preclinical development for selected indications. The partnership combines Insilico’s AI-driven molecule design with Eli Lilly’s expertise in clinical development and commercialization.
Alex Zhavoronkov, founder and CEO of Insilico Medicine, said the collaboration demonstrates the potential of AI to tackle complex medical challenges. “From its inception, Insilico Medicine has been developing deep learning for end-to-end drug discovery. Working with Lilly, we aim to deliver transformative therapies that treat diseases with high unmet need,” he said.
Insilico Medicine is a clinical-stage biotechnology company that uses its Pharma.AI platform to integrate biology, chemistry, and clinical analysis. The system identifies new disease targets and designs drug molecules, aiming to reduce the time and cost of bringing therapies from concept to clinic.
Andrew Adams, group vice president of molecule discovery at Eli Lilly, described the partnership as a strategic complement to the company’s research capabilities. “Insilico’s AI-enabled discovery capabilities represent a powerful complement to Lilly’s deep expertise in clinical development across multiple therapeutic areas,” he said. “This partnership allows us to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas.”
Financial terms of the agreement include a $115 million (€100 million) upfront payment to Insilico Medicine. Additional payments tied to development, regulatory, and commercial milestones could increase the total deal value to $2.75 billion (€2.39 billion), with tiered royalties on future sales.
The collaboration highlights a growing trend in the pharmaceutical industry, where companies are increasingly integrating artificial intelligence into research and development processes. By using AI to predict molecular interactions and optimize drug candidates, companies aim to reduce development timelines and bring more effective therapies to patients faster.
Industry analysts note that partnerships like this could redefine how new drugs are discovered, particularly for complex diseases where traditional methods have faced high failure rates. For Eli Lilly, the agreement represents a step toward combining digital innovation with established clinical expertise to address unmet medical needs worldwide.
With the deal now in place, both companies will work closely to move AI-designed therapies from preclinical stages toward clinical trials, potentially transforming the landscape of pharmaceutical development in the coming years.
